JCVI: Duck Hepatitis B Virus DNA Copy Numbers in Isolated Hepatocyte Nuclei Vary Dramatically and Decline During Entecavir Therapy.
 
 
Section Banner

Publications

Citation

Shen G, Fu X, Zhou B, Yin J, Zhong C, Chen J, Hou J

Duck Hepatitis B Virus DNA Copy Numbers in Isolated Hepatocyte Nuclei Vary Dramatically and Decline During Entecavir Therapy.

Antiviral Therapy. 2013 Jun 14;

External Citation

Abstract

BACKGROUND: We aimed to develop a quantitative assay to measure duck hepatitis B virus (DHBV) DNA in single hepatocyte nuclei from DHBV-infected animals and to observe intranuclear DHBV DNA kinetics undergoing entecavir (ETV) therapy. METHODS: DHBV DNA in isolated nuclei was amplified by quantitative real-time polymerase chain reaction (PCR). Liver tissues from chronically infected ducks with or without ETV treatment were assessed. Cell cycle phases were defined with flow cytometry in single nuclei. RESULTS: We successfully established a quantitative assay to measure intranuclear DHBV DNA in single nuclei with high specificity, sensitivity and acceptable interassay variations. The intranuclear viral DNA copy numbers varied dramatically (2-204 copies/nuclei) in 11 ducks with active viral replication. Average intranuclear DHBV DNA copies from individual animals (7.57-57.67/nuclei) significantly correlated with total intranuclear (rs = 0.955, P < 0.001) and serum (rs = 0.745, P = 0.008) viral DNA levels. The median intranuclear DHBV DNA copies in virus-positive nuclei were greater in G0/1 than those in G2/M and S phases (P < 0.001). Median intranuclear viral DNA copies in virus-positive nuclei decreased from 21 to 6 (P < 0.001) under 14-19 weeks of ETV therapy. However, subsequently, no further reductions were not achieved in 4 animals after extended 16 week treatment (6 vs. 11, P = 0.034). CONCLUSIONS: Intranuclear DHBV DNA levels varied significantly, which could be partially attributed to impacts from cell cycle phases, and could be decreased by ETV therapy.